GLP-1 Drugs and Pancreatitis: Is the Risk Real or Overstated? | Research

The takeaway

GLP-1 receptor agonists are frequently associated with GI side effects (up to 80% of patients), but the association with acute pancreatitis remains debated and may be overstated based on current evidence.

Up to 80% GI effects
GI side effects are very common with GLP-1 drugs but usually dose-dependent and manageable; pancreatitis risk may be overstated

What the researchers found

GI adverse effects affect up to 80% of GLP-1 RA users in a dose-dependent manner, but the association with acute pancreatitis remains uncertain and may be overstated based on current pharmacovigilance and clinical trial evidence.

Why it matters

The pancreatitis concern has been a significant barrier to GLP-1 drug prescribing. Clarifying this risk helps patients and clinicians make informed decisions about these widely used medications.

How the study worked

Narrative review of clinical trial data and pharmacovigilance reports on GLP-1 RA gastrointestinal safety, with focus on the pancreatitis question.

What this study cannot tell us

Narrative review without systematic analysis. Pancreatitis is rare, making it difficult to study definitively in clinical trials. Post-marketing surveillance has inherent biases.

How to read the evidence

Narrative review of available clinical trial and pharmacovigilance evidence. Provides perspective but not definitive resolution.

When this study was published

Published in 2025, addressing an ongoing safety debate.

The bigger picture

As GLP-1 drugs expand to new indications (MASLD, cardiovascular protection), ensuring an accurate safety profile is essential for appropriate use in millions of patients.

Questions still open

Would large prospective registries definitively resolve the GLP-1-pancreatitis question?
Do certain GLP-1 drugs carry different pancreatitis risk profiles?
Should patients with prior pancreatitis avoid GLP-1 drugs entirely?

Common questions

Can GLP-1 drugs cause pancreatitis?

The concern exists from early reports, but controlled clinical trials and reviews have not clearly confirmed an increased risk. Most experts consider the risk, if it exists, to be small and potentially overstated.

Are stomach side effects from GLP-1 drugs serious?

Nausea, vomiting, and diarrhea are common (up to 80% of patients) but usually mild, dose-dependent, and improve with time. Slow dose titration helps minimize these effects.

Read the original research

GLP-1 receptor agonists and acute pancreatitis: fact or overstated risk?

Revista espanola de enfermedades digestivas, 118(1), 64-65

View on PubMed ↗Publisher’s paper ↗

Citation

Domínguez Muñoz, Juan Enrique; Lariño Noia, José; Domínguez Novoa, Yessica; Iglesias-García, Julio. (2026). GLP-1 receptor agonists and acute pancreatitis: fact or overstated risk?. Revista espanola de enfermedades digestivas, 118(1), 64-65. https://doi.org/10.17235/reed.2025.11499/2025